## BCR-ABL Fusion Protein and CML Pathogenesis **Key Point:** The BCR-ABL fusion protein is a constitutively active tyrosine kinase that drives chronic myeloid leukemia (CML) through uncontrolled phosphorylation of downstream signaling proteins, independent of growth factor stimulation. ### Philadelphia Chromosome: t(9;22) Translocation The t(9;22) translocation juxtaposes: - **ABL** (Abelson tyrosine kinase) from chromosome 9 - **BCR** (Breakpoint Cluster Region) from chromosome 22 - Result: **BCR-ABL** fusion gene encoding a 210 kDa protein ### Mechanism of Leukemogenesis ```mermaid flowchart TD A[t 9;22 translocation] --> B[BCR-ABL fusion protein] B --> C[Constitutive tyrosine kinase activity] C --> D[Phosphorylation of downstream proteins] D --> E[Activation of RAS/MAPK, PI3K/AKT, JAK/STAT pathways] E --> F[Uncontrolled myeloid proliferation] E --> G[Impaired apoptosis] E --> H[Reduced adhesion to bone marrow stroma] F --> I[CML] ``` ### Why BCR-ABL Drives CML 1. **Constitutive kinase activity** — BCR-ABL phosphorylates target proteins WITHOUT requiring ligand binding or growth factor stimulation 2. **Multisite phosphorylation** — Activates RAS/MAPK, PI3K/AKT, JAK/STAT, and other survival/proliferation pathways 3. **Impaired apoptosis** — Upregulates anti-apoptotic proteins (BCL-2, MCL-1) 4. **Altered adhesion** — Reduces interaction with bone marrow stromal cells, allowing leukemic blasts to escape the niche **High-Yield:** BCR-ABL is the classic example of an oncogenic fusion protein. It is targetable by tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib), which revolutionized CML treatment. **Clinical Pearl:** Imatinib (Gleevec) was the first targeted cancer drug approved by the FDA (2001) and dramatically improved CML survival from ~5 years to >20 years. This exemplifies precision medicine in oncology.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.